FIELD : medicine. SUBSTANCE : present group of inventions relates to neurology, and concerns the treatment of Alzheimer' s disease. For this purpose, in addition to the acetylcholinesterase inhibitor, N-(2-(6-fluoro-1H-indole-3-yl)ethyl-(2, 2, 3, 3-tetrafluoropropoxy)benzylamine or its pharmaceutically acceptable salt is introduced daily in a dose of 30–60 mg. EFFECT : invention provides effective treatment by enhancing the effect of an acetylcholinesterase inhibitor. 13 cl, 13 dwg, 3 tbl, 3 ex